Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0605
D

Failure to Assess and Address Unnecessary Antipsychotic Medication Use

Wheeler, Oregon Survey Completed on 06-26-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to ensure that a resident with dementia was free from unnecessary use of antipsychotic medication. The resident was admitted with diagnoses including a stage four pressure ulcer and dementia, and was prescribed multiple psychoactive medications, including quetiapine, trazodone, venlafaxine, Namenda, and hydroxyzine. Despite the presence of symptoms and side effects associated with psychoactive medication use, as evidenced by increasing Abnormal Involuntary Movement Scale (AIMS) scores, the facility did not adequately assess the continued need for antipsychotic medication. The physician was notified of certain symptoms and reduced the dose of venlafaxine, but did not address the use of quetiapine. The Psychotropic Committee did not order additional gradual dose reductions (GDRs) or assess the appropriateness of continued antipsychotic use despite adverse side effects. Observations and staff interviews indicated that the resident did not exhibit negative behaviors or signs of distress, and staff reported that calling out behaviors had lessened and were not distressing to the resident. However, the facility relied on pharmacist reviews rather than conducting their own assessments for antipsychotic medication use. Facility leadership acknowledged that antipsychotic medication was prescribed to address calling out behaviors that were disturbing to others, but not distressing to the resident, and admitted that a comprehensive risk/benefit assessment should have been completed in light of the adverse side effects.

An unhandled error has occurred. Reload 🗙